
ME THERAPEUTICS RECEIVES SUPPORT TO ADVANCE mRNA THERAPEUTIC CANDIDATES FOR CANCER AND INFLAMMATORY DISEASE
ME Therapeutics Holdings Inc. (METX:CSE), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of Immuno-Oncology, is pleased to provide an overview and update on our current research and development programs.